Literature DB >> 26323027

Near Full-Length Genomic Characterization of a Novel CRF 01_AE/C Recombinant from Western India.

Santosh Karade1,2, Sudhanshu Pandey1, Sheetal Gianchandani1, Swarali N Kurle1, Manisha Ghate3, Nitin S Gaikwad4, Bharat B Rewari5, Raman R Gangakhedkar3.   

Abstract

HIV is known for its genetic variability across the globe. The HIV epidemic in India is primarily driven by subtype C, although sporadic circulating and unique recombinant forms are also reported from a few metropolitan cities in which genotyping facilities are available. Here we report a novel CRF01_AE/C recombinant from a multicenter study on the effectiveness of antiretroviral therapy (ART), 12 months after its initiation. Our subject is a 32-year-old heterosexual female, a native of Pune city in western India. Identification and analyses of recombination breakpoints using jpHMM@Gobics and SimPlot bootscanning revealed six recombination breakpoints, indicating insertion of the CRF01_AE genome at three points in the backbone of subtype C. Both subtype C and CRF01_AE are commonly seen in the population at risk of heterosexual HIV transmission, thereby providing an opportunity for cocirculation and recombination. The emergence of a novel recombinant of CRF01_AE/C is indicative of the increasing genetic diversity of the HIV epidemic in India.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26323027     DOI: 10.1089/aid.2015.0228

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  1 in total

1.  Cross-sectional study of virological failure and multinucleoside reverse transcriptase inhibitor resistance at 12 months of antiretroviral therapy in Western India.

Authors:  Santosh K Karade; Manisha V Ghate; Devidas N Chaturbhuj; Dileep B Kadam; Subramanian Shankar; Nitin Gaikwad; Shraddha Gurav; Rajneesh Joshi; Suvarna S Sane; Smita S Kulkarni; Swarali N Kurle; Ramesh S Paranjape; Bharat B Rewari; Raman R Gangakhedkar
Journal:  Medicine (Baltimore)       Date:  2016-09       Impact factor: 1.889

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.